Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in recurrent high-grade glioma
NCT04822805Phase 2Unknown
- Sponsor
- Hangzhou First People's Hospital
- Start
- Apr 2020
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in glioma, sponsored by Hangzhou First People's Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04822805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822805.